Workshop To Address Public Interest And CRISPR Gene Editing, CAR T Cancer Treatment 04/09/2017 by Intellectual Property Watch Leave a Comment Experts at a one-day workshop in Washington DC next week will discuss public interest aspects of patents and two breakthrough new medical technologies related to gene editing (CRISPR) and cancer treatment (CAR T).
Industry Study Looks At Economics Of Trademark-Intensive Industries In SE Asia 30/08/2017 by Intellectual Property Watch Leave a Comment A trademark industry study released today looks at the economic contribution of trademark-intensive industries in five countries in the Southeast Asian region, and finds they are making a significant contribution. The study puts a particular focus on Singapore.
Deadline Next Week For Swedish Sida Training On Genetic Resources And IP Regulation 25/08/2017 by Intellectual Property Watch 1 Comment Applications are due by 4 September for an all-expenses-paid Swedish International Development Cooperation Agency (Sida) Advanced International Training Programme aimed at building capacity in intellectual property and genetic resources in support of innovation.
Access To Medicines Foundation Details Methodology For 2018 AMR Benchmark 24/08/2017 by Intellectual Property Watch Leave a Comment The Amsterdam-based Access to Medicines Foundation today published the methodology it will use for its 2018 framework for evaluating how pharmaceutical companies are taking action to limit antimicrobial resistance, addressing the rising the global problem of overuse of antibiotics leading to resistance with few new ones in the pipeline.
INTA Pro Bono Trademark Clearinghouse Takes Off 23/08/2017 by Intellectual Property Watch Leave a Comment This summer, the International Trademark Association (INTA), the global trademark industry group, launched a one-of-a-kind pilot program offering pro bono attorneys the opportunity to help nonprofits and others obtain and protect trademarks. And in its first weeks, it is already receiving submissions and a positive response, according to an INTA representative.
India Grants Pfizer Patent On Pneumonia Vaccine, Stokes Fear Of Unaffordability 22/08/2017 by Intellectual Property Watch Leave a Comment MUMBAI (Reuters) – India has granted Pfizer Inc a patent for its powerful pneumonia vaccine Prevenar 13, in a blow to some health groups that said this would put the treatment out of reach of thousands in poorer nations.
Qatar WTO Complaint: Saudi, UAE, Bahrain Restrictions Violate IP Rights 04/08/2017 by Intellectual Property Watch 2 Comments The government of Qatar has requested World Trade Organization dispute settlement consultations with the United Arab Emirates, Bahrain and Saudi Arabia over restrictions ranging from goods and services, to airspace, to intellectual property rights. In the filing, Qatar complains the countries are engaging in “coercive attempts at economic isolation.”
More Than Half Of People With HIV Now Have Access To Treatment, UNAIDS Says 20/07/2017 by Intellectual Property Watch Leave a Comment For the first time, more than half of people in the world living with HIV have access to treatment, UNAIDS said in a report released today in Geneva. In addition, AIDS-related deaths have been nearly cut in half since 2005, it said. As of 2016, nearly 20 million people were living with HIV.
USTR Puts IP Focus In Digital Trade In NAFTA Renegotiation Objectives 18/07/2017 by Intellectual Property Watch Leave a Comment In its newly issued objectives for renegotiation of the North American Free Trade Agreement (NAFTA), the Office of the United States Trade Representative (USTR) has put a strong focus on protecting and exploiting intellectual property rights in the digital environment.
Temporary Compulsory License For Antiretroviral Drug Upheld By German Court 17/07/2017 by Intellectual Property Watch 1 Comment MUNICH — The German Federal Supreme Court in a decision drawing significant attention on 11 July upheld a temporary compulsory licence granted for the HIV drug Isentress (X ZB 2/17). The antiretroviral drug, based on raltegravir, has been the object of a prolonged court fight between Japanese drug company Shionogi and its US competitor Merck.